Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019
New York City
Friday, October 4 at 7:45 a.m. Eastern time (ET).
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Jefferies Healthcare Conference Presentation – June 2019
ObsEva Investor Presentation – April 2019
ObsEva Short Report 2018
Press Releases
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019
press release
August 9, 2019
Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
press release
August 7, 2019
Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Read moreObsEva Reports Second Quarter 2019 Financial Results
press release
Multiple Major Milestones Expected This Year Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban Nolasiban MAA…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Event
October 17, 2019
Stock Information
Latest Press Release
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Christophe Lamps
Dynamics Group
+41 79 476 26 87
Media United States
Marion Janic
RooneyPartners LLC
+1 212-223-4017
Contacts
Sign up for news
